Research Projects Will Use Real-World Evidence to Support People Living With Type 1 Diabetes
BOSTON and INDIANAPOLIS, April 9, 2014 /PRNewswire/ -- T1D Exchange and Eli Lilly and Company (NYSE: LLY) announced today they have entered into a research collaboration that will enable both organizations to gain deeper, real-world insight about the experience of people with type 1 diabetes, to identify new ways to improve care and advance outcomes.
As part of this multi-year collaboration, the organizations will engage in a range of projects that combine Lilly's long history of and expertise in type 1 diabetes with T1D Exchange's innovative, patient-centric model that connects a clinic registry of more than 26,000 people with T1D, a clinic network comprised of more than 70 clinics across the U.S., a sample repository that stores patient biosamples and Glu, a patient and caregiver online community for T1D. The collaboration will involve multiple projects over an initial five-year period.
"Lilly's commitment to supporting people with type 1 diabetes dates back to 1923, when we introduced the first commercially available insulin," said Dara Schuster, M.D., Medical Fellow, Lilly Diabetes. "Having access to the resources of T1D Exchange to bolster our understanding of the needs of people with type 1 diabetes, their caregivers and health care providers will help us continue our mission of addressing the global diabetes burden through the development of innovative medicines and programs."
The first project of the collaboration will assess user experience associated with insulin pumps and multiple daily injections. Initially, T1D Exchange data will be analyzed to inform development of a survey of health care providers from the clinic network and members of the Glu community. Following the survey, a study of clinic registry participants is planned, to further shed light on how insulin pumps are used and how multiple daily injections occur in real-world practice. Data and recommendations from this research will be shared publicly once analysis is complete, for the benefit of both the type 1 diabetes and researcher communities.
"The T1D Exchange Clinic Registry was established to provide real-world data on a large number of children and adults with type 1 diabetes to serve as a resource for both academic and company researchers," said Dr. Roy Beck, Director, T1D Exchange Clinic Coordinating Center, Executive Director, JAEB Center for Health Research. "This collaboration with Lilly is a great example of how the registry data can be used to address key issues that are important to individuals with type 1 diabetes."
About T1D Exchange
T1D Exchange, the first program of Unitio, was founded on the premise that finding faster, better therapies for type 1 diabetes (T1D) requires a research model as multi-faceted as the disease itself. T1D Exchange acts as a convener of the thousands of people working to improve patient outcomes already—by connecting them to one another and to the patient community at large. Drawing on decades of research and data that have come before, T1D Exchange aims to be the translational engine that enables the entire T1D ecosystem to collaborate in truly novel ways via the integration of a Clinic Network, Clinic Registry, Sample Repository, and the online patient/caregiver community, Glu. For more information, please visit unitio.org/pages/t1d-exchange.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels.
FOR MORE INFORMATION CONTACT:
Eli Lilly and Company
SOURCE Eli Lilly and Company